Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHWay: Adjuvant Pembrolizumab in High-Risk Head and Neck Cancer
NCT02841748Phase 2Completed
- Sponsor
- University of Chicago
- Start
- May 2017
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Chicago. Started May 2017; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02841748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841748.